Inhaled liposomal amikacin

Expert Rev Respir Med. 2014 Aug;8(4):401-9. doi: 10.1586/17476348.2014.918507. Epub 2014 May 31.


Arikace™ is a novel formulation of inhaled liposomal amikacin that can penetrate deep within airway secretions and within Pseudomonas aeruginosa biofilms, making it an attractive therapeutic option for the treatment of cystic fibrosis (CF) pulmonary infections. Initial Phase I and Phase II studies in CF patients with chronic P. aeruginosa infection demonstrated that Arikace™ was a safe drug that resulted in significant improvements in lung function after 14-28 days of treatment. Phase III studies of inhaled liposomal amikacin compared to tobramycin inhalation solution in CF patients with P. aeruginosa infection revealed a comparable increase in forced expiratory volume in 1 second at the end of three cycles. In addition, inhaled liposomal amikacin has other potential applications in the management of difficult-to-treat pulmonary infections. A Phase II trial is currently underway to study the use of Arikace™ for the treatment of recalcitrant nontuberculous mycobacterial lung disease.

Keywords: amikacin; clinical trial; cystic fibrosis; inhalation; pseudomonas.

Publication types

  • Review

MeSH terms

  • Administration, Inhalation
  • Amikacin / administration & dosage
  • Amikacin / therapeutic use*
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / therapeutic use*
  • Cystic Fibrosis / complications*
  • Humans
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / etiology
  • Pseudomonas aeruginosa
  • Respiratory Tract Infections / drug therapy*
  • Respiratory Tract Infections / etiology
  • Treatment Outcome


  • Anti-Bacterial Agents
  • Amikacin